

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF THE CLAIMS:

1-4. (cancelled)

5. (currently amended) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence of SEQ ID NO:13 selected from the group consisting of:

- ~~(a) — a mature form of an amino acid sequence comprising SEQ ID NO:13;~~
- ~~(b) — a variant of a mature form of an amino acid sequence comprising SEQ ID NO:13, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;~~
- ~~(c) — an amino acid sequence comprising SEQ ID NO:13;~~
- ~~(d) — a variant of an amino acid sequence comprising SEQ ID NO:13, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence;~~
- ~~(e) — a nucleic acid fragment encoding at least a portion of a polypeptide comprising an amino acid sequence comprising SEQ ID NO:13, or a variant of said polypeptide, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence; and~~
- ~~(f) — a nucleic acid molecule comprising the complement of (a), (b), (c), (d) or (e).~~

6-8. (canceled) The nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises the nucleotide sequence of a naturally-occurring allelic nucleic acid variant.

9. (currently amended) The nucleic acid molecule of claim 5, wherein said nucleic acid molecule comprises a nucleotide sequence of SEQ ID NO:12:

- ~~(a) — a nucleotide sequence comprising SEQ ID NO: 12;~~
 - ~~(b) — a nucleotide sequence differing by one or more nucleotides from a nucleotide sequence comprising SEQ ID NO: 12, provided that no more than 20% of the nucleotides differ from said nucleotide sequence;~~
 - ~~(c) — a nucleic acid fragment of (a); and~~
 - ~~(d) — a nucleic acid fragment of (b).~~
10. (currently amended) The nucleic acid molecule of claim 5, wherein said nucleic acid molecule hybridizes under stringent conditions to a nucleotide sequence consisting of SEQ ID NO: 12, ~~or a complement of said nucleotide sequence.~~
11. (canceled)
12. (currently amended) A vector comprising the nucleic acid molecule of claim ~~11~~ 5.
13. (original) The vector of claim 12, further comprising a promoter operably-linked to said nucleic acid molecule.
14. (original) A cell comprising the vector of claim 12.
- 15-18. (canceled)
19. (original) A method for determining the presence or amount of the nucleic acid molecule of claim 5 in a sample, the method comprising:
- (a) providing the sample;
 - (b) contacting the sample with a probe that binds to said nucleic acid molecule; and
 - (c) determining the presence or amount of the probe bound to said nucleic acid molecule,
- thereby determining the presence or amount of the nucleic acid molecule in said sample.

Applicants: Gerlach et al
U.S.S.N.: 09/964,956

20. (currently amended) ~~The~~ A method of claim 19 wherein presence or amount of the nucleic acid molecule is used as a marker for cell or tissue type.
21. (original) The method of claim 20 wherein the cell or tissue type is cancerous.
- 22-38. (canceled)
39. (original) A pharmaceutical composition comprising the nucleic acid molecule of claim 5 and a pharmaceutically-acceptable carrier.
- 40-49. (cancelled)
50. (new) An isolated nucleic acid molecule comprising a nucleic acid sequence, wherein said nucleic acid sequence is a complement of SEQ ID NO: 13.